December 18, 2020 -- ONK Therapeutics has signed three licensing agreements for natural killer (NK) cell therapy products.
The first agreement is with Cellerant Therapeutics which gives ONK exclusive rights to a humanized C-type lectin domain family 12 member A (CLEC12A) single-chain variable fragment (scFv) binder. ONK plans to combine CLEC12A chimeric antigen receptor (CAR) with a tumor necrosis factor (TNF)-related apoptosis-inducing ligand variant targeting death receptor 4; it will be used in patients with acute myeloid leukemia.
Under the second agreement, ONK will license a humanized, tumor-specific antibody targeting an aberrantly glycosylated tumor-associated form of MUC1 from Glycotope and will integrate this antibody into its preclinical program for solid tumors.
Finally, ONK is licensing a CC-chemokine receptor 7 (CCR7) homing receptor from the U.S. National Institutes of Health (NIH) for use in its preclinical program for relapsed/refractory B-cell cancer.
Copyright © 2020 scienceboard.net